STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Active, not recruiting
- Lymphoma, B-Cell
- San Antonio, TexasMays Cancer Center, UT Health San Antonio
2022-03-09
Mar 9, 2022U
Completed
- Lymphoma, B-Cell
- Montpellier, FranceUh Montpellier
2021-11-12
Nov 12, 2021T
Withdrawn
- Lymphoma, B-Cell
- TAC01-CD19
- (no location specified)
2022-02-07
Feb 7, 2022L
Not yet recruiting
- Lymphoma, Non-Hodgkin Lymphoma, B-Cell
- BAFF CAR-T
- (no location specified)
2022-04-01
Apr 1, 2022C
Not yet recruiting
- High-grade B-cell Lymphoma
- +8 more
- Sepantronium Bromide
- Busan, Korea, Republic of
- +5 more
2022-02-27
Feb 27, 2022H
Recruiting
- Lymphoma, B-Cell
- Rituximab Biosimilar
- Pegylated Interferon α-2b
- Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
2022-04-06
Apr 6, 2022U
Not yet recruiting
- Lymphoma, B-Cell
- CD19 redirected autologous T cells (CTL019 or CTL119 cells)
- Philadelphia, PennsylvaniaUniversity of Pennsylvania
2022-03-18
Mar 18, 2022N
Terminated
- Lymphoma, B-Cell
- +3 more
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-01-26
Jan 26, 2022U
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022N
Active, not recruiting
- Leukemia, B-cell
- +3 more
- Allogeneic stem cell transplant
- +2 more
- Bethesda, Maryland
- +1 more
2022-04-07
Apr 7, 2022S
Recruiting
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +4 more
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- R-CHOP; R-DA-EPOCH; R-HD MTX
- Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital
2021-12-07
Dec 7, 2021C
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +3 more
- (no location specified)
2021-07-20
Jul 20, 2021S
Recruiting
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- +4 more
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
- Jinan, Shandong, ChinaShandong Provincial Hospital
2021-11-18
Nov 18, 2021C
Recruiting
- Leukemia
- +4 more
- CD19 CAR-T cells
- Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force
2021-03-01
Mar 1, 2021U
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Pembrolizumab
- +4 more
- (no location specified)
2022-02-02
Feb 2, 2022I
Recruiting
- B-cell Non-Hodgkin's Lymphoma
- Cincinnati, OhioThe Christ Hospital
2022-04-01
Apr 1, 2022I
Recruiting
- Diffuse Large B-cell Lymphoma
- Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
- Toulouse, FranceInstitut Universitaire du Cancer Toulouse - Oncopole
2022-03-28
Mar 28, 2022M
Recruiting
- Lymphoma, Non-Hodgkin
- +4 more
- Rochester, MinnesotaMayo Clinic
2021-08-30
Aug 30, 2021F
G
Completed
- Non-Hodgkin's Lymphoma
- Lymphoma, B-Cell
- radiolabeled epratuzumab
- (no location specified)
2021-08-12
Aug 12, 2021I
Withdrawn
- Diffuse Large B Cell Lymphoma
- +3 more
- CD19 t-haNK
- El Segundo, CaliforniaChan Soon-Shiong Institute for Medicine
2021-05-14
May 14, 2021R
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- (no location specified)
2021-12-27
Dec 27, 2021S
Completed
- Lymphoma, Large B-Cell, Diffuse
- FDG PET radiomic feature evaluation
- Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
2021-09-27
Sep 27, 2021B
Suspended
- B-cell Non-Hodgkin's Lymphoma
- CD19/CD20 Dual-CAR-T cells
- Beijing, Beijing, ChinaBeijing Tsinghua Changgung Hospital
2022-01-29
Jan 29, 2022B
Not yet recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- loncastuximab tesirine
- Detroit, MichiganBarbara Ann Karmanos Cancer Institute
2022-01-24
Jan 24, 2022